Serum albumin-fused interleukin-33 suppresses experimental autoimmune encephalomyelitis

Immunoregulatory cytokine, interleukin-33 (IL-33) is known to suppress experimental autoimmune encephalomyelitis (EAE), but its clinical utility is hindered by poor pharmacokinetics and toxicity.

The researchers develop a fusion of serum albumin and IL-33 (SA-IL33) with reduced toxicity and prolonged lymph node residence.

SA-IL-33 prevents the onset of and suppresses established inflammation-mediated paralysis in mice with superior efficacy compared to WT IL-33 , demonstrating promise as a therapeutic for neuroinflammatory diseases.

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00304-0

https://sciencemission.com/serum-albumin-fused-interleukin-33